Sven Andreasson

Sven Andréasson has more than 30 years’ experience as an executive in the life science industry. He started his career at Kabi, Stockholm, where he became CEO for the German, UK and Belgian subsidiaries. He subsequently became head of the Biopharmaceutical division responsible for human growth hormones, blood plasma products, and LMW heparin/ thrombolytic cardiovascular products. After the acquisition of Pharmacia in 1989 he became President of Pharmacia International in Brussels, Belgium and later Pharmacia SA, Paris, France (today part of Pfizer). From 1999 he served for nine years as the President and CEO of Active Biotech, Lund Sweden, a publicly traded company developing innovative products for autoimmune diseases including multiple sclerosis (partnered with TEVA) and for various cancers. He subsequently became CEO of Beta-Cell NV, in Brussels, a company developing cell-based treatments for diabetes. In February 2012 he became CEO of Isconova AB, a vaccine development company acquired by Novavax Inc, Rockville, MD, where he is Senior VP, Corporate Development. Sven Andréasson has an MSc in business administration and finance from the Stockholm School of Economics.